Trial
NCT04831450
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Miami
Collaborators
Regeneron Pharmaceuticals
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Cemiplimab-Rwlc
Why stopped
Investigator Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-04